[Targeted therapies in soft-tissue and visceral sarcomas].
Emile
Jean-François
JF
EA4340, université de Versailles SQY, hôpital Ambroise-Paré, AP-HP, avenue Charles-de-Gaulle, Boulogne, France. jean-francois.emile@apr.aphp.fr
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D002869:Chromosome Aberrations; D016503:Drug Delivery Systems / Q000379:methods*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D014781:Viscera
D000970:Antineoplastic Agents; D001549:Benzamides; D009363:Neoplasm Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit